Exicure (NASDAQ:XCUR – Get Free Report) released its earnings results on Friday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($18.60) by $18.31, FiscalAI reports.
Exicure Trading Up 5.7%
Shares of NASDAQ XCUR traded up $0.17 during mid-day trading on Friday, hitting $3.14. The company had a trading volume of 11,159 shares, compared to its average volume of 25,631. The company has a market capitalization of $20.00 million, a price-to-earnings ratio of -4.08 and a beta of 3.62. Exicure has a 1 year low of $2.63 and a 1 year high of $10.80. The stock’s 50-day moving average price is $3.67 and its 200-day moving average price is $4.42.
Exicure Company Profile
Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.
The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.
Read More
- Five stocks we like better than Exicure
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
